Healthcare Leaders Hub

🏠Home 📰News 📝Blog 🎬Videos Advertise Login

Your trusted source for pharmaceutical news, expert insights, and healthcare innovation.

💼𝕏 👥▶️

Content

📰News
📝Blog
🎬Videos

Company

🏠Home
🏢About Us
📧Contact

© 2026 PharmaVoice. All rights reserved. Empowering healthcare leaders.

Privacy Policy•Terms of Service

Pharma Tech

MSD bets $2.13bn on SciBrunch’s KRAS (ON) inhibitor

Sep 29, 2026, 10:32 AM

Read Full Article → MSD bets $2.13bn on SciBrunch’s KRAS (ON) inhibitor

MSD bets $2.13bn on SciBrunch’s KRAS (ON) inhibitor

Translate article text

Choose a language and wait for the translated text.

MSD's bet on targeting RAS comes amid the industry buzz around the approval of Revolution's OS-doubling pancreatic cancer drug, Rasonque.

MSD bets $2.13bn on SciBrunch’s KRAS (ON) inhibitor | PharmaVoice